



Nanotechnology in Ovarian Cancer: Diagnosis and Treatment

Guest Editor:

Dr. Shailendra Kumar Dhar Dwivedi

Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma, OK 73104, USA

Deadline for manuscript submissions:

25 October 2024

Message from the Guest Editor

Ovarian cancer is frequently diagnosed at an advanced stage, posing challenges due to limited efficacious treatment options. Nanotechnology presents groundbreaking avenues to enhance early detection, precision drug delivery, and customized therapeutic interventions for individuals affected by ovarian cancer. In this Special Issue, we seek to publish cutting-edge research highlighting the latest advancements in the following areas:

Targeted Drug Delivery Approach

Hyperthermia Therapy

Nanoparticle-based Biomarker Detection

Nanoparticle-based Biosensors

In this Special Issue, we invite contributions that showcase the forefront of research in these areas, shedding light on the potential transformative impact of nanotechnology in the diagnosis and treatment of ovarian cancer.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)